T he innate immune response is critical to our survival as human beings. An important component of the innate immune response is the release of myeloperoxidase (MPO) predominantly from neutrophils upon activation. MPO generates numerous reactive oxidant species and has the unique ability to produce reactive chlorinating species which are particularly potent against invading viruses and bacteria (1) . However, innate immunity can also be involved in causing disease and has been shown to play a critical role in the pathogenesis of coronary artery disease (CAD), myocardial infarction (MI), and heart failure (2) . While some immune effects may be similarly beneficial in CAD, the majority of immune contributions, and particularly those of neutrophil-derived MPO, seems to wreak inflammatory havoc culminating in atherosclerosis progression, plaque instability, acute coronary syndromes, and adverse ventricular remodeling following MI (3).
MPO seems like an obvious target for CAD and heart failure therapies. As early as the 1960s, the key role of MPO in the innate immune response was gaining interest (4) . The realization that MPO and its products were expressed in human atherosclerotic plaque, first noted in the 1990s, sparked intense in- Virginia, Charlottesville, Virginia. Dr. Taylor has reported that she has no relationships relevant to the contents of this paper to disclose. shown to be a better predictor of cardiac death and MI than high-sensitivity C-reactive protein or troponin (9, 10) . Additionally, MPO predicted adverse event rates in systolic and diastolic heart failure, predicted progression of heart failure, and more accurately predicted the risk of endothelial dysfunction compared to high-sensitivity C-reactive protein (11, 12) . Indeed, the cumulative literature suggested that MPO could be used to predict vulnerable plaque and risk stratify all things cardiac. However, in the years that followed these initial observations, numerous papers contradicted these findings or at best failed to corroborate them (13) (14) (15) . Following this, interest in MPO as a major mechanism of CAD and heart failure declined, aside Myeloperoxidase has been implicated as a key contributor to several aspects of coronary artery disease development, plaque destabilization, and myocardial injury, making it an attractive therapeutic target. amt6b@virginia.edu.
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